A CooDerative Studv on ProMACE-dytaBOM in Aggressive Non-Hodgkin's Lymphomas

References

• Coltman C.A., Dahlberg S., Jones S.E., et al. CHOP is curative in thirty percent of patients with large cell lym-phoma: a twelve-year Southwest Oncology Group follow-up. Proc. Am. Soc. Clin. Oncol. 1986; 5: 197
   Google Scholar
• Fisher R.I., Miller T.P., Dana B.W., Jones S.E., Dahlberg S., Coltman C.A., Jr. Southwest Oncology Group clinical trials for intermediate and high-grade non-Hodgkin's lymphomas. Semin. Hematol. 1987; 24(suppl. l)21–25
   PubMedGoogle Scholar
• Jones S.E., Grozea P.N., Miller T.P., Van Slick E.J., et al. Chemotherapy with cyclophosphamide, doxo-rubicin, vincristine and prednisone alone or with levamisole or with levamisole plus BCG for malignant lymphoma: Southwest Oncology Group Study. J. Clin. Oncol. 1985; 3: 1318–1324
   PubMed Web of Science ®Google Scholar
• Connors J.M., Klimo P. MACOP-B chemotherapy for malignant lymphomas and related conditions: 1987 update and additional observations. Semin. Hematol. 1988; 25(Suppl. 2)41–48
   PubMed Web of Science ®Google Scholar
• Fisher R.I., De Vita V.T., Jr., Hubbard S.M., Ihde D.G., Longo D.L., Phares J.C., et al. Randomized trial of ProMACE-MOPP vs ProMACE-CytaBOM in previously untreated, advanced stage, diffuse aggressive lymphomas. Proc. Am. Soc. Clin. Oncol. 1984; 3: 242
   Google Scholar
• Goldie J.H., Coldman A.J. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep. 1979; 63: 1727–1733
   PubMedGoogle Scholar
• Guglielmi C., Amadori S., Anselmo A.P., Baroni C.D., et al. Sequential combination chemotherapy of high-grade non-Hodgkin's lymphoma with 5-fluorouracil, metho-trexate, cytosine-arabinoside, cyclophosphamide, doxorubicin, vincristine and prednisone (F-MACHOP). Cancer Invest. 1987; 5: 139–169
   Web of Science ®Google Scholar
• Klimo P., Connors J.M. MACOP-B chemotherapy for the treatment of diffuse large cell lymphoma. Ann. Intern. Med. 1985; 102: 596–602
   PubMed Web of Science ®Google Scholar
• Longo D.L., De Vita V.T., Jr., Duffey P., et al. Randomized trial of ProMACE-MOPP (day 1–8) vs Pro-MACE-CytaBOM in stage II-IV aggressive non-Hodgkin's lymphoma. Proc. Am. Soc. Clin. Oncol. 1987; 6: 206
   Google Scholar
• O'Reilly S., Klimo P., Connors J.M. Low-dose ACOP-B and VABE chemotherapy for elderly patients with advanced-stage diffuse large-cell lymphoma. J. Clin. Oncol. 1991; 9: 741–747
   PubMed Web of Science ®Google Scholar
• Weick J.K., Dahlberg S., Fisher R.I., Dana B., et al. Combination chemotherapy of intermediate-grade and high-grade non-Hodgkin's lymphoma with MACOP-B: A Southwest Oncology Group Study. J. Clin. Oncol. 1991; 9: 748–753
   PubMed Web of Science ®Google Scholar
• Kaplan E.L., Maier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958; 53: 457–481
   Web of Science ®Google Scholar
• Hryniuk W., Bush H. The importance of dose intensity in chemotherapy of metastatic breast carcinoma. J. Clin. Oncol. 1984; 2: 1281–1288
   PubMed Web of Science ®Google Scholar
• Fisher R.I., Longo D.L., De Vita V.T., Jr., Hubbard S.M., Miller T.P., Young R.C. Long term follow-up of ProMACE-CytaBOM in non-Hodgkin's lym-phomas. Ann. Oncol. 1991; 2(suppl. l)33–35
   PubMedGoogle Scholar
• Longo D.L., De Vita V.T., Jr., Duffey P.L., Wesley M.N., Ihde D.C., et al. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. J. Clin. Oncol. 1991; 9: 25–38
   PubMed Web of Science ®Google Scholar
• Miller T.P., Dahlberg S., Weick J.K., Files J.C., Eyre H.J., Pendergrass K.B., Fisher R.I. Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: A Groupwide Southwest Oncology Group Study. J. Clin. Oncol. 1990; 8: 1951–1958
   PubMed Web of Science ®Google Scholar
• Federico M., Moretti G., Gobbi P.G., Avanzini P., et al. ProMACE-Cyta BOM versus MACOP-B in intermediate and high grade NHL. Preliminary results of a prospective randomized trial. Leukemia (suppl.)
   Google Scholar
• Capucci M.A., Bonfanti V., Ferremi P., Mariano M.R., et al. Risultati a lungo termine di un prodotto differ-enziato nel trattamento del linfomi non Hodgkin. Haemato-logica 1991; 76(suppl. no. 2)80–82
   PubMedGoogle Scholar
• Cavalli F. Chemotherapy of non-Hodgkin's lympho-mas. Chemotherapy of Malignant Blood Disease, R.A. Zihoun, 1991; 157–179, Clin. Hematol.
   Google Scholar
• Coiffier B., Gisselbrecht C., Vose J.M., Tilly H., et al. Prognostic factors in aggressive malignant lympho-mas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. J. Clin. Oncol. 1991; 9: 211–219
   PubMed Web of Science ®Google Scholar
• Hoskins P.J., Ng V., Spinelli J.J., Klimo P., Connors J.M. Prognostic variables in patients with diffuse large-cell lymphoma treated with MACOP-B. J. Clin. Oncol. 1991; 9: 220–226
   PubMed Web of Science ®Google Scholar
• Otter R., Gemts W. B. J., Sandt V.D., Hermans J., Willemze R. Primary extranodal and nodal non-Hodgkin's lymphoma. A survey of a population-based registry. Eur. J. Cancer Clin. Oncol. 1989; 25: 1203–1210
   PubMedGoogle Scholar
• Robertson L.E., Redman J.R., Butler J.J., Osborne B.M., Velasquez W.S., Mc Laughlin P., et al. Discordant bone marrow involvement in diffuse large-cell lymphoma: a distinct clinical-pathologic entity associated with a continuous risk of relapse. J. Clin. Oncol. 1991; 9: 236–242
   PubMed Web of Science ®Google Scholar
• Velasquez W.S., Fuller L.M., Jagannath S., Tucker S.L., et al. Stage I and II diffuse large cell lymphomas: prognostic factors and long-term results with CHOP-Bleo and radiotherapy. Blood 1991; 77: 942–947
   PubMed Web of Science ®Google Scholar
• Epelbam R., Faraggi D., Ben-Arie Y., et al. Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables. Cancer 1990; 66: 1124–1129
   PubMed Web of Science ®Google Scholar
• Kwak L.W., Halpern Y., Olsen R.A., et al. Prognostic significance of actual dose intensity in diffuse large cell lymphoma: results of a tree-structured survival analysis. J. Clin. Oncol. 1990; 5: 756–765
   Google Scholar
• Browne M.J., Hubbard S.M., Longo D.L., et al. Excess prevalence of Pneumocystis carinii pneumonia in patients treated for lymphoma with combination chemotherapy. Ann. Intern. Med. 1986; 104: 338–344
   PubMed Web of Science ®Google Scholar